Browse
You are looking at 31 - 40 of 63 items for
Search for other papers by Nathan J Graham in
Google Scholar
PubMed
Search for other papers by Joshua D Smith in
Google Scholar
PubMed
Search for other papers by Tobias Else in
Google Scholar
PubMed
Search for other papers by Gregory J Basura in
Google Scholar
PubMed
Head and neck paragangliomas (HNPGLs) are slow-growing, vascular, typically benign tumors whose growth may induce significant lower cranial nerve deficits. While most tumors arise sporadically, a significant portion is associated with defined genetic syndromes. While surgical resection has historically been the gold standard, management strategies have evolved with acknowledgement of high surgical morbidity, slow tumor growth rates, and technological advances. Conservative management approaches via observation and newer radiation therapy techniques have become more common. This review seeks to provide an update on contemporary management strategies for HNPGLs and future directions.
Search for other papers by Donatella Treppiedi in
Google Scholar
PubMed
Search for other papers by Rosa Catalano in
Google Scholar
PubMed
Search for other papers by Federica Mangili in
Google Scholar
PubMed
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Search for other papers by Giovanna Mantovani in
Google Scholar
PubMed
Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Search for other papers by Erika Peverelli in
Google Scholar
PubMed
Cell cytoskeleton proteins are involved in tumor pathogenesis, progression and pharmacological resistance. Filamin A (FLNA) is a large actin-binding protein with both structural and scaffold functions implicated in a variety of cellular processes, including migration, cell adhesion, differentiation, proliferation and transcription. The role of FLNA in cancers has been studied in multiple types of tumors. FLNA plays a dual role in tumors, depending on its subcellular localization, post-translational modification (as phosphorylation at Ser2125) and interaction with binding partners. This review summarizes the experimental evidence showing the critical involvement of FLNA in the complex biology of endocrine tumors. Particularly, the role of FLNA in regulating expression and signaling of the main pharmacological targets in pituitary neuroendocrine tumors, pancreatic neuroendocrine tumors, pulmonary neuroendocrine tumors and adrenocortical carcinomas, with implications on responsiveness to currently used drugs in the treatment of these tumors, will be discussed.
Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic
Search for other papers by Alexander Kreze in
Google Scholar
PubMed
Search for other papers by Matěj Homer in
Google Scholar
PubMed
Search for other papers by Tereza Barešová in
Google Scholar
PubMed
Search for other papers by Kristina Klemperová in
Google Scholar
PubMed
Summary
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described.
Learning points
-
Treatment with immune checkpoint inhibitors (ICIs) is associated with many endocrine side effects.
-
It is recommended that patients treated with ICIs are observed by an endocrinologist.
-
If side effects are treated accordingly, ICI therapy can continue.
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia
Search for other papers by Krishna Vikneson in
Google Scholar
PubMed
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia
Search for other papers by Tariq Haniff in
Google Scholar
PubMed
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by May Thwin in
Google Scholar
PubMed
Search for other papers by Ahmad Aniss in
Google Scholar
PubMed
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Alex Papachristos in
Google Scholar
PubMed
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Mark Sywak in
Google Scholar
PubMed
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, St. Vincent’s Clinical School, Faculty of Medicine, University of New South Wales Sydney, Sydney, New South Wales, Australia
Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
Search for other papers by Anthony Glover in
Google Scholar
PubMed
Objectives
For small thyroid cancers (≤2 cm), tumour volume may better predict aggressive disease, defined by lymphovascular invasion (LVI) than a traditional single measurement of diameter. We aimed to investigate the relationship between tumour diameter, volume and associated LVI.
Methods
Differentiated thyroid cancers (DTC) ≤ 2 cm surgically resected between 2007 and 2016 were analysed. Volume was calculated using the formula for an ellipsoid shape from pathological dimensions. A ‘larger volume’ cut-off was established by receiver operating characteristic (ROC) analysis using the presence of lateral cervical lymph node metastasis (N1b). Logistic regression was performed to compare the ‘larger volume’ cut-off to traditional measurements of diameter in the prediction.
Results
During the study period, 2405 DTCs were surgically treated and 523 met the inclusion criteria. The variance of tumour volume relative to diameter increased exponentially with increasing tumour size; the interquartile ranges for the volumes of 10, 15 and 20 mm diameter tumours were 126, 491 and 1225 mm3, respectively. ROC analysis using volume to predict N1b disease established an optimal volume cut-off of 350 mm3 (area under curve = 0.59, P = 0.02) as ‘larger volume’. ’Larger volume’ DTC was an independent predictor for LVI in multivariate analysis (odds ratio (OR) = 1.7, P = 0.02), whereas tumour diameter > 1 cm was not (OR = 1.5, P = 0.13). Both the volume > 350 mm3 and dimension > 1 cm were associated with greater than five lymph node metastasis and extrathyroidal extension.
Conclusion
In this study for small DTCs ≤ 2 cm, the volume of >350 mm3 was a better predictor of LVI than greatest dimension > 1 cm.
Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for other papers by Erina Iwabuchi in
Google Scholar
PubMed
Search for other papers by Yasuhiro Miki in
Google Scholar
PubMed
Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan
Search for other papers by Takashi Suzuki in
Google Scholar
PubMed
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
In hormone-dependent cancers, the activation of hormone receptors promotes the progression of cancer cells. Many proteins exert their functions through protein–protein interactions (PPIs). Moreover, in such cancers, hormone–hormone receptor binding, receptor dimerization, and cofactor mobilization PPIs occur primarily in hormone receptors, including estrogen, progesterone, glucocorticoid, androgen, and mineralocorticoid receptors. The visualization of hormone signaling has been primarily reported by immunohistochemistry using specific antibodies; however, the visualization of PPIs is expected to improve our understanding of hormone signaling and disease pathogenesis. Visualization techniques for PPIs include Förster resonance energy transfer (FRET) and bimolecular fluorescence complementation analysis; however, these techniques require the insertion of probes in the cells for PPI detection. Proximity ligation assay (PLA) is a method that could be used for both formalin-fixed paraffin-embedded (FFPE) tissue as well as immunostaining. It can also visualize hormone receptor localization and post-translational modifications of hormone receptors. This review summarizes the results of recent studies on visualization techniques for PPIs with hormone receptors; these techniques include FRET and PLA. In addition, super-resolution microscopy has been recently reported to be applicable to their visualization in both FFPE tissues and living cells. Super-resolution microscopy in conjunction with PLA and FRET could also contribute to the visualization of PPIs and subsequently provide a better understanding of the pathogenesis of hormone-dependent cancers in the future.
Search for other papers by Damien A Leach in
Google Scholar
PubMed
Search for other papers by Rayzel C Fernandes in
Google Scholar
PubMed
Search for other papers by Charlotte L Bevan in
Google Scholar
PubMed
Androgen signalling, through the transcription factor androgen receptor (AR), is vital to all stages of prostate development and most prostate cancer progression. AR signalling controls differentiation, morphogenesis, and function of the prostate. It also drives proliferation and survival in prostate cancer cells as the tumour progresses; given this importance, it is the main therapeutic target for disseminated disease. AR is also essential in the surrounding stroma, for the embryonic development of the prostate and controlling epithelial glandular development. Stromal AR is also important in cancer initiation, regulating paracrine factors that excite cancer cell proliferation, but lower stromal AR expression correlates with shorter time to progression/worse outcomes. The profile of AR target genes is different between benign and cancerous epithelial cells, between castrate-resistant prostate cancer cells and treatment-naïve cancer cells, between metastatic and primary cancer cells, and between epithelial cells and fibroblasts. This is also true of AR DNA-binding profiles. Potentially regulating the cellular specificity of AR binding and action are pioneer factors and coregulators, which control and influence the ability of AR to bind to chromatin and regulate gene expression. The expression of these factors differs between benign and cancerous cells, as well as throughout disease progression. The expression profile is also different between fibroblast and mesenchymal cell types. The functional importance of coregulators and pioneer factors in androgen signalling makes them attractive therapeutic targets, but given the contextual expression of these factors, it is essential to understand their roles in different cancerous and cell-lineage states.
Search for other papers by Kiyoshi Takagi in
Google Scholar
PubMed
Search for other papers by Mio Yamaguchi in
Google Scholar
PubMed
Search for other papers by Minoru Miyashita in
Google Scholar
PubMed
Department of Pathology, Tohoku University Hospital, Sendai, Japan
Search for other papers by Hironobu Sasano in
Google Scholar
PubMed
Search for other papers by Takashi Suzuki in
Google Scholar
PubMed
Breast cancer is a hormone-dependent cancer, and sex steroids play a pivotal role in breast cancer progression. Estrogens are strongly associated with breast cancers, and the estrogen receptor (estrogen receptor α; ERα) is expressed in 70–80% of human breast carcinoma tissues. Although antiestrogen therapies (endocrine therapies) have significantly improved clinical outcomes in ERα-positive breast cancer patients, some patients experience recurrence after treatment. In addition, patients with breast carcinoma lacking ERα expression do not benefit from endocrine therapy. The androgen receptor (AR) is also expressed in >70% of breast carcinoma tissues. Growing evidence supports this novel therapeutic target for the treatment of triple-negative breast cancers that lack ERα, progesterone receptor, and human EGF receptor 2, and ERα-positive breast cancers, which are resistant to conventional endocrine therapy. However, the clinical significance of AR expression is still controversial and the biological function of androgens in breast cancers is unclear. In this review, we focus on the recent findings concerning androgen action in breast cancers and the contributions of androgens to improved breast cancer therapy.
Search for other papers by Ana Rita Elvas in
Google Scholar
PubMed
Search for other papers by Andreia Martins Fernandes in
Google Scholar
PubMed
Search for other papers by Sara Reis in
Google Scholar
PubMed
Search for other papers by Joana Couto in
Google Scholar
PubMed
Search for other papers by Raquel G Martins in
Google Scholar
PubMed
Search for other papers by Jacinta Santos in
Google Scholar
PubMed
Search for other papers by Teresa Martins in
Google Scholar
PubMed
Endocrinology Department, Egas Moniz Hospital, West Lisbon Hospital Center E.P.E., Lisboa, Portugal
Search for other papers by Bernardo Marques in
Google Scholar
PubMed
Search for other papers by Joana Guimarães in
Google Scholar
PubMed
Search for other papers by Fernando J C Rodrigues in
Google Scholar
PubMed
Summary
Primary hyperparathyroidism (PHPT) is the unregulated overproduction of parathyroid hormone (PTH), resulting in abnormal calcium homeostasis. PHPT is most commonly caused by a single adenoma of the parathyroid gland, which can have an intrathyroid location in rare cases. The measurement of intact PTH in the washout fluid obtained by ultrasound (US)-guided fineneedle aspiration (FNA) can be useful in clarifying the aetiology of these lesions. This study presented a 48-year-old man with a background history of symptomatic renal stone disease who was diagnosed with PHPT and referred to our Endocrinology department. A neck US revealed a thyroid nodule with a size of 21 mm in the right lobe. The patient underwent US-guided FNA of the lesion. The measurement of PTH in the washout fluid was significantly elevated. Following the procedure, he reported neck pain and noticed distal paraesthesias in the upper limbs. Blood test results showed significant hypocalcaemia and supplementation with calcium and calcitriol was started. The patient was closely monitored. Recurrence of hypercalcaemia was later observed, and the patient was submitted to surgery. We present a case of FNAinduced transitory remission of PHPT in a patient with an intrathyroid parathyroid adenoma. We conjecture that intra-nodular haemorrhage might have occurred, which temporarily affected the viability of the autonomous parathyroid tissue. A few similar cases of spontaneous or induced remission of PHPT after FNA have been previously described in the literature. This remission can be transitory or permanent, depending on the degree of cellular damage thus follow-up of these patients is recommended.
Search for other papers by Poh Shean Wong in
Google Scholar
PubMed
Search for other papers by Subashini Rajoo in
Google Scholar
PubMed
Search for other papers by Hairuddin Achmad Sankala in
Google Scholar
PubMed
Search for other papers by Mohamed Badrulnizam Long Bidin in
Google Scholar
PubMed
Summary
Pituitary metastasis (PM) is a rare complication of an advanced malignancy. Albeit rare, PM can be more detected and achieve a longer survival rate through frequent neuroimaging and newer oncology therapies. Lung cancer is the most frequent primary site, followed by breast and kidney cancers. Patients with lung cancer generally present with respiratory symptoms and are commonly diagnosed at an advanced stage already. Nevertheless, physicians should be mindful of other systemic manifestations as well as signs and symptoms related to metastatic spread and paraneoplastic syndromes. Herein, we report the case of a 53-year-old woman who presented with PM as the first sign of an undiagnosed lung cancer. Initially, her condition was a challenging diagnosis and was even complicated with diabetes insipidus (DI), which can present as severe hyponatremia when coexisting with adrenal insufficiency. This case also highlights that treating DI with antidiuretic hormone (ADH) replacement was complicated by extreme difficulties in attaining satisfactory sodium and water balance during the clinical course, with the possibility of coexistent DI and syndrome of inappropriate ADH secretion because of the underlying lung cancer.
Learning points
-
When patients present with pituitary mass and diabetes insipidus (DI), pituitary metastasis should be considered as an initial differential diagnosis. DI caused by pituitary adenoma is rare and is typically a late finding.
-
DI can present as severe hyponatremia when coexisting with adrenal insufficiency.
-
Cortisol can directly inhibit endogenous antidiuretic hormone (ADH) secretion. Patients with adrenocorticotropic hormone deficiency will have increased tonic ADH activity and subsequently reduced capacity for free-water excretion. However, when on steroid therapy, patients should be monitored for possible DI because steroids can restore free-water excretion.
-
A substantial change in serum sodium after desmopressin treatment should eliminate the possibility of desmopressin overdose or coexistence of DI and syndrome of inappropriate ADH secretion in patients with lung cancer. Therefore, frequent monitoring of serum sodium concentrations is crucial.
Department of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas, USA
Search for other papers by Ruaa Al-Ward in
Google Scholar
PubMed
Search for other papers by Celeste Zsembery in
Google Scholar
PubMed
Search for other papers by Mouhammed Amir Habra in
Google Scholar
PubMed
Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer. The current treatment recommendations and guidelines for adjuvant therapy are mostly derived retrospectively from national databases and the treatment outcomes of patients seen in referral centers. To better select patients for adjuvant therapy, multiple factors need to be considered including staging, markers of cellular proliferation (such as Ki67%), resection margins, hormonal function, and possibly genetic alterations of the tumor as well as patient-related factors such as age and performance status. Adjuvant mitotane remains the most commonly used adjuvant therapy in ACC based on clinical practice guidelines, though emerging data from ADIUVO trial (mitotane vs observation in low-risk ACC) suggest that mitotane use in low-risk patients may not be needed. An ongoing clinical trial (ADIUVO-2) is evaluating the role of mitotane vs mitotane combined with chemotherapy in high-risk ACC. The use of adjuvant therapy has been controversial but can be justified in select patients with positive resection margins or after the resection of localized recurrence. A prospective study is needed to study the role of adjuvant radiation in ACC as radiation is expected to help only with local control without impact on distant microscopic metastases. There are no recommendations or published data about using adjuvant immunotherapy in ACC, but this may be a future study after establishing the efficacy and safety profile of immunotherapy in metastatic ACC.
